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Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide with
a poor prognosis. Human papilloma virus (HPV) infection is associated with 20% HNSCC, and 50% of oropharyngeal
carcinoma. HPV16 type is detected in 90% of all HPV+ HNSCC. Recently we suggested a fundamentally different
approach to treatment of cancers of viral origin by targeting viral antigens on cancer cells with radiolabeled antibodies
(mAbs) which promises exquisite specificity of treatment. We aimed at extending this approach to HPV-related head and
neck cancer by performing radioimmunotherapy (RIT) targeting E6 and E7 oncogenes with radiolabeled mAbs.
Methods: We first aimed at developing HPV16+ cell line and animal model for RIT of HNSCC as at present there are
no commercially available HPV16+ HNSCC cell lines and there is only one HPV+ cell line among the collection
maintained by Dusseldorf, Michigan and Turku groups. Commercially available HNSCC cell line FaDu was transfected
with pLXSN16E6E7 vector containing HPV16 E6 and E7 genes. Generated novel cell lines were evaluated by PCR and
western blot and the tumorigenecity was assessed in nude mice. Proof of principle RIT targeting E6 oncoprotein in
2A3 tumor-bearing nude mice was conducted using unlabeled or 188-Rhenium (
188Re)-labeled C1P5 mAb to E6.
Results: Novel HPV16+ 2A3 cell line reliably expressed E6 oncoprotein. E6 expression was modifiable with
proteasome inhibitor MG132 in a dose-dependent manner. The levels of E6 expression in 2A3 cell line were
estimated to be around 200 HPV copies per cell. The HPV16+ 2A3 cell line preserved 100% tumorigenicity of parent
FaDu cells in nude mice. During RIT of 2A3 tumors in nude mice the relatively low dose of 200 μCi
188Re-C1P5 mAb
was effective in decreasing the tumor growth in comparison with untreated controls. Unlabeled C1P5 mAb also
caused some decrease in tumor progression, however, much less pronounced than
188Re-C1P5 mAb.
Conclusions: We describe a proof-of-principle RIT study targeting HPV16 E6 oncoprotein with radiolabeled mAb to
E6 in a stably transformed HPV16+ HNSCC cell line and tumor model in nude mice, and demonstrate potential
utility of RIT as a novel molecular targeted therapy for HNSCC.
Background
Oncogenic HPV infection is a causative factor in more
than 90% of cervical cancers in women. It is also a risk
factor for the development of penile and vulvar cancers.
HPV infection is associated with a subset of head and
neck squamous cell carcinomas (HNSCC), which are the
sixth most common malignancy worldwide. HPV DNA
is found in ~20% HNSCC, and ~50% of oropharyngeal
carcinomas. HPV type 16 is the most prevalent and is
found in 90% of all HPV positive HNSCC [1]. Onco-
genicity in tumors caused by HPV is due to the preva-
lence of early genes E6 and E7 which disrupt normal
cell growth and inhibit tumor-suppressor proteins. The
viral oncoproteins E6 and E7 immortalize epithelial cells
in culture and increase cellular transformation in con-
cert with other oncoproteins [2-4]. E6 oncoprotein are
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rapid degradation via the ubiquitin-dependent pathway,
while E7 oncoprotein bind to the retinoblastoma (Rb)
gene, thus causing ineffective cell growth regulation. As
a consequence, the clinical outcomes for HPV-positive
(HPV+) and HPV-negative (HPV-) head and neck
cancers are often different [5].
Radioimmunotherapy (RIT) uses tumor antigen-specific
monoclonal antibodies (mAbs) for targeted delivery of
cytocidal ionizing radiation to the tumor cells [6]. Radiola-
beled mAbs have been approved for the treatment of pri-
mary, recurrent or refractory non-Hodgkin lymphoma
(NHL). Our laboratory is interested in developing new
therapies for HPV-related cancers based on RIT targeting
E6 and E7 oncogenes with the radiolabeled mAbs [7]. Pre-
viously we showed the feasibility of targeting E6 oncopro-
tein in experimental cervical cancer by using radiolabeled
mAb to E6 as a selective mediator of tumor destruction
[8-10]. Though E6 and E7 oncoproteins are intranuclear
and are not accessible to the mAbs in viable tumor cells -
in fast growing tumors cellular turnover releases E6 and
E7 oncoproteins into the extracellular space where they
can be targeted for delivery of cytotoxic radiation by radi-
olabeled E6 or E7-binding mAbs via so called “cross-fire”
effect (radiation emanating from one cell hitting the
distant cell) (Figure 1). Naturally, for the development of
RIT of HPV+ HNSCC it is important to have well charac-
terized HPV+ HNSCC cell lines. However, at present
there are no commercially available HPV+ HNSCC
cell lines. Among the 29 HNSCC cells lines described in
[11] such as cell lines maintained by the University of
Michigan, University of Turku and University of Dussel-
dorf groups - only one cell line UD-SCC 2 is listed at
HPV+ [11]. In this study we describe the generation of a
stably transformed HPV16+ positive HNSCC cell line
derived from the widely used and commercially available
cell line, FaDu [12]. With this novel cell line we estab-
lished a mouse model of HPV-associated head and neck
cancer and conducted proof of principle RIT experiments
with radiolabeled E6-specific mAb.
Materials and methods
Cell lines, Antibodies, and Reagents
FaDu and PA317 LXSN 16E6/E7 cell lines were procured
from American Type Culture Collection (ATCC, Mana-
ssas, VA) and grown in DMEM media containing 10%
Fetal Bovine Serum (Fisher) and 1% penicillin-streptomycin
solution (penicillin, 10,000 U; streptomycin, 10 mg/mL;
both from Fisher) at 37°C in a 5% CO2 incubator. The cell
lines FaDu and PA317 were screened for mycoplasma by
the manufacturer, ATCC, using both the Hoechst DNA
stain and direct culture method. The antibiotics amount in
the cell culture medium is recommended by ATCC and is
considered inconsequential for cellular responses. The
FaDu line was established in 1968 from a punch biopsy of
a hypopharyngeal tumor. PA317 LXSN 16E6/E7 is a packa-
ging cell line developed by transfection of the retrovirus
vector pLXSN16E6/E7 into the Psi-2 ecotropic packaging
cell line. The pLXSN16E6E7 vector contains the human
papilloma virus (HPV) type 16 E6 and E7 genes under con-
trol of the Moloney murine leukemia virus (MoMuLV)
promoter-enhancer sequences. The vector also contains a
gene encoding resistance to neomycin transcribed from the
SV40 promoter. This line produces the amphotropic retro-
virus LXSN16E6/E7 encoding the HPV16 E6 and E7 open
reading frames, which have been used to stably infect and
immortalize many cell types. Cervical carcinoma HPV16-
p o s i t i v eC a s K ic e l ll i n e( A T C C )w a sg r o w na si n[ 6 ] .
Murine anti-HPV16-E6, C1P5 antibody (IgG1 isotype) was
obtained from Abcam (Boston, MA). Proteasome inhibitor
MG-132 was purchased from Calbiochem (San Diego, CA)
and BD Matrigel Basement Membrane Matrix - from BD
Biosciences (Rockville, MD). The beta-emitter
188Re with a
half life of 16.9 hours was produced from beta decay of
188-Tungsten parent (half life 69 days) using a
188W/
188Re
generator (Oak Ridge National Laboratory, Oak Ridge,
TN). After
188Re was eluted in the form of sodium perrhe-
nate, the C1P5 mAb was labeled “directly” with
188Re
through binding of reduced
188Re to the generated -SH
groups on the mAb as previously described [8-10].
Transfection of FaDu cells with HPV16 Oncogenes E6 and E7
Transfection of the FaDu cell line with the HPV16
oncogenes E6 and E7 of PA317 LXSN16E6/E7 was per-
formed by growing PA317 LXSN16E6/E7 cells in
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Figure 1 Diagram detailing mechanism of HPV+ RIT with
radiolabeled mAbs to intracellular antigens E6 and E7.
Intracellular antigens E6 and E7 are released from cancer cells as a
consequence of a cellular turnover in a fast-growing tumor. E6 or
E7-specific mAbs bind to extracellular E6 and E7 and deliver
cytotoxic radiation to the area. The viable tumor cells including
those with no or weak E6 or E7 expression are killed by radiation
through “cross-fire” effect by radiation emitted in 360° sphere.
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changed and 16 hours after incubation with fresh media,
the media containing the virus was removed and passed
through a 0.4 μm low protein binding filter to remove
cells and debris. The supernatant containing the virus
was kept for further use. The FaDu cells were incubated
under the same conditions until ~60% confluence. One
mL of viral supernatant was combined with 3 mL of
serum-free DMEM containing 4 μg/mL hexadimethrin
bromide (polybrene) (Sigma) and overlaid onto the
FaDu cells in 75 cm
2 flasks. After incubation for
3 hours, another 5 mL of serum-free DMEM containing
4 μg/mL polybrene was added to the flasks and incu-
bated for another 4 hours. The media/viral supernatant
mixture was then removed and 25 mL of complete
DMEM was added to each flask, which were incubated
for another 48 hours. Selection of transfected cells was
done using the neomycin analogue, G418 (1 mg/mL)
(Fisher), for 7 days. The surviving cells were then cul-
tured with complete DMEM containing 200 μg/mL
G418 for the duration of the project. Pure colonies were
established by serially diluting the surviving cells in a
96-well plate. Wells containing only one cell were
grown and eventually transferred to 75 cm
2 flasks for
further propagation. The growth of the transfected cells
was compared to that of FaDu cells for 6 days and dou-
bling times for both cell lines were calculated using the
following formula:
Doubling time ln2 ln(A Ao) t  where A amount of cells at  /( / / ),    time t
Ao amount of cells at time 
,
. 0
DNA Extraction and PCR
Polymerase Chain Reaction (PCR) was used to deter-
mine the presence of oncogenes E6 and E7 in the trans-
fected cell lines. DNA from the colony purified line was
extracted and purified using the DNeasy Blood & Tissue
Kit obtained from Invitrogen. The concentration of
DNA was measured spectrophotometrically at 260 nm
wavelength using a Spectra Max 250 96-well plate
reader. The following oligonucleotides (Invitrogen) were
used: E6F1 5’-ATGTTTCAGGACCCACAGGA-3’; E6R1
5’-GGTTTCTCTACGTGTTCTTGA-3’;E 7 R 15 ’-TCC
AGCTGGACCATCTATTTC-3’.T h eE 6a n dE 7o n c o -
genes overlap on the vector thus allowing for two pro-
ducts - E6 alone and E6 + E7. Platinum PCR SuperMix
High Fidelity from Invitrogen was added to each PCR
reaction tube along with 150 ng of genomic DNA, and
3.0 μL of primer (300 nM). The tubes were incubated
initially at 94°C for 1 min to denature the template and
to activate the enzyme followed by 40 temperature
cycles of: 95°C for 30 seconds, 50°C for 40 seconds,
68°C for 40 seconds. DNA from CasKi cells which have
high number (~ 600) of HPV16 copies per cell was used
as positive control.
Western Blotting
Western blotting was performed to establish the pre-
sence of E6 oncoproteins in the transfected FaDu cells
as well as to estimate the level of E6 expression in this
cell line in comparison with cervical cancer cell line
CasKi. Cell pellets were suspended in the lysis buffer
(4% SDS, 20% glycerol, 0.5 M TrisHCl (pH 6.8), 0.002%
bromophenol blue and 10% b-mercaptoethanol). Protein
samples were boiled in water for 5 min before running
SDS-PAGE. Twenty five to thirty μl of protein solution
was loaded into each well of 12% pre-cast SDS-PAGE
gel (Bio-Rad). SDS-PAGE was used to monitor the rela-
tive protein amounts in the samples. All samples were
normalized with a tubulin control. Twelve percent SDS-
PAGE gel was used to separate proteins, and electro-
phoresis was performed using Mini-Protean
® 3C e l l
system (Bio-Rad). After electrophoresis, the gel was
transferred into the PVDF transfer buffer (25 mM Tris,
190 mM glycine and 2.5% (v/v) methanol) for 5 min.
Then, proteins were transferred from the gel to the
Immun-Blot™ PVDF membrane (Bio-Rad) on Semi-dry
Electrophoretic Transfer Cell (Bio-Rad) at 15 V for
17 min. The membrane was soaked in the blocking
solution (5% non-fat dry milk in the 0.1% TBST) with
gentle shaking for one hour. The membrane was incu-
bated in TBST blocking solution (0.1% Tween-20,
25 mM TrisHCl (pH 7.6), 500 mM NaCl, and 5% non-
fat dry milk) containing 1:2000 diluted anti-HPV16 E6
C1P5 mAb at 4°C overnight. After several washes with
TBST, the membrane was hybridized by the secondary
antibody conjugated with horseradish peroxidase (Rabbit
polyclonal to mouse IgG (HRP)) in TBST blocking solu-
tion with a 1:10,000 dilution. After three washes with
TBST, the membrane was incubated with Rodeo ECL
detection reagents 1 and 2 (USB) for 5 min, and then
exposed to CL-XPosure™ film (Pierce). The film was
developed as per manufacturer’s instructions. For esti-
mation of E6 level in HPV transfected FaDu cells - the
western blotts of this and of CasKi cell lines were sub-
jected to ImageJ intensity quantification.
Tumor Model
All animal studies were carried out in accordance with
the guidelines of the Institute for Animal Studies at the
Albert Einstein College of Medicine. 6-8 weeks-old athy-
m i cN u / N uC D 1n u d em i c ew e r ep u r c h a s e df r o m
Charles River Laboratories. Ten million HPV transfected
FaDu cells (3-4 passaging of cells) were mixed with 80%
Matrigel and injected subcutaneously into the right flank
of each mouse. The size of the tumors was measured
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Fowler Tools and Instruments, Boston, MA) in three
dimensions and the tumor volume was calculated as a
product of three dimensions divided by 2. Electronic cali-
pers help to ensure the precision of measurement and
allow the immediate download of the measurements into
the Excel file for tumor volume calculations, groups ran-
domization etc.
MG132 Treatment of Transfected FaDu Cells in vitro and
in vivo
To study the response of HPV-transfected FaDu cells to
MG-132 (Z-LLL-CHO, MW = 457.6) which is a potent,
reversible and cell-permeable proteasome inhibitor (Ki =
4 nM) - the original and transfected FaDu cells were har-
vested and transferred into 4 sterile test tubes with com-
plete media. Each tube contained 0.5 - 1 ml cell culture
(cell concentration was ~10
6 cells/ml), and cells were
a l l o w e dt og r o wa t3 7 ° Ci n5 %C O 2 incubator overnight.
Then, MG-132 solution was added to the tubes for the
final concentrations of 0, 5, 10 or 25 μg/ml. The cells were
incubated under the same conditions for another 3 hours.
Finally, the cells were harvested by centrifugation, clarified
by washing with PBS and processed for western blot as
described above. For in vivo investigation of the MG-132
influence on the level of E6 expression in HPV-transfected
FaDu tumors, 3 mice carrying tumors were injected intra-
peritoneally (IP) with 20 μg MG-132 and another group of
3 transfected tumor-bearing mice was used as control.
Three hours later, all mice in both groups were sacrificed,
their tumors removed, homogenized on ice and processed
for western blot as described above.
RIT of Transfected FaDu Tumors
To investigate the utility of the transfected FaDu cell
line as a basis for an animal model for drug develop-
ment, we conducted a proof of principle RIT study tar-
geting E6 oncoprotein with
188Re-labeled C1P5 mAb.
The mice with transfected FaDu tumors measuring
0.5-0.7 cm in diameter were randomized into groups of
five. The groups were treated IP with either: 200 μCi
188Re-C1P5 mAb, matching amount (6 μg) of unlabeled
("cold”) C1P5 mAb; or left untreated. The mice were
observed for tumor growth and survival for 15 days.
The experiment was performed twice.
Statistical Analysis
Student t-test was performed to compare the doubling
times for FaDu and transfected cell lines. The sample
sizes in the animal experiments were pre-planned. The
differences between the tumor sizes for differently
treated groups in the RIT studies were analyzed by
non-parametric Mann-Whitney test using Prism soft-
ware (GraphPad, San Diego, CA). The differences were
considered statistically significant when p-values
were < 0.05.
Results
Generation and characterization of HPV16+ cell line
After transfection a total of 10 new HPV16+ cell lines
were produced. Cell line 2A3 was selected for further
characterization as it most reliably expressed E6/E7 as
demonstrated by PCR (Figure 2). Transfection was
stable as the cells of >50 passages were still consistently
expressing E6. Propagation the 2A3 cells in vitro
demonstrated that they grew in culture in the same
fashion as the parent cell line FaDu (Figure 3). Their
doubling time of 51.8 hrs was no different from FaDu
cells (48.1 hrs, P > 0.05). The 2A3 cells showed stable
expression of E6 oncoprotein (Figure 4a). Comparison
of E6 level in 2A3 using ImageJ quantification to that in
cervical cancer CasKi cell line which has 600 HPV
copies per cell revealed that amount of E6 in 2A3 cells
should be equivalent to approximately 200 HPV copies
per 2A3 cell (Figure 4b).
E6 levels in 2A3 cells were responsive to treatment
with the MG-132 proteasome inhibitor, 10 μg/ml
resulted in increased levels of E6 oncoprotein in the
cells at 3 hrs post-treatment while the effect of the
higher concentrations of MG-132 plateaued at 25 μg/ml
(Figure 4c).
In vivo characterization of HPV16+ 2A3 cell line
To test if the 2A3 cell line preserved the tumorigenecity
of the parent FaDu cells in nude mice and continued to
express E6 oncoprotein in vivo, we initiated xenografts in
the flanks of female nude mice. The tumorigenecity rate
of 2A3 cell line was 100% with 20 out of 20 mice devel-
oping tumors of 0.5-0.7 cm in diameter 10 days post
inoculation with the cells. The tumors expressed high
levels of E6 oncoproteins as demonstrated by western
blot which were also increased up to 3 hrs post-treatment
of tumor-bearing mice with MG-132 (Figure 4d).
S i n c ew ea r ei n t e r e s t e di nd e v e l o p i n gm A b s - b a s e d
therapies for head and neck cancers by targeting E6 or
E7 oncoproteins with radiolabeled mAbs to these pro-
teins, we conducted a proof of principle RIT study in
2A3 tumor-bearing mice with
188Re-C1P5 mAb, or
Figure 2 PCR for HPV16 transfection. Three cell lines were
assessed at >P15 for both E6 and E7 oncogenes with total cellular
DNA (lanes 1 and 2 - FaDu E6/E6E7, lanes 3 and 4 - CasKi E6/E6E7,
lanes 5 and 6 - 2A3 E6/E7).
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untreated mice as controls (Figure 5). The relatively low
dose of 200 μCi
188Re-C1P5 mAb was significantly effec-
tive in decreasing the tumor growth in comparison with
untreated controls throughout the experiment (Table 1).
Therapeutic effect of RIT was most apparent in the
early time intervals studied. “Cold” C1P5 mAb also
caused some decrease in tumor progression though not
as dramatic as
188Re-C1P5 mAb - tumor regression was
significantly more pronounced in RIT group than in
“cold” mAb group on Days 3-9 post treatment (Table 1).
Discussion
T h eH N S C Ci sc h a r a c t e r i z e db yap o o rp r o g n o s i sa n d
novel, effective therapeutic options are urgently needed.
A significant percentage of HNSCC’sa r eH P V 1 6 + .
The absence of a commercially available HPV16+ cell
line hinders the research effort in developing new drugs
for this disease. Though many laboratories cultivate
their own HNSCC cell lines [11] - only one of them is
reported to be HPV+. In addition, one fundamental and
irrevocable requirement for the utilization of cell lines is
their well-identified origin as well as the exclusion of
cross-contamination by prokaryotic or eukaryotic cells.
Thus, a straight-forward and reliable method of generat-
ing a HPV16+ HNSCC cell line using a commercial
parent cell line and transfection reagents would be
extremely useful in the field.
We generated a stably transformed HPV16+ cell line
2A3 derived from the widely used and commercially
available cell line FaDu [12]. Expression of E6/E7 onco-
genes in this novel cell line as determined by PCR was
similar to that in patients when PCR was used [13]; from
the comparison of western blot data with the well charac-
terized cervical cancer cell line CasKi we estimated that
2A3 cell line has approximately 200 HPV copies per cell.
Importantly for drug discovery research - this cell line
was 100% tumorigenic in nude mice while continuing to
express E6 oncoprotein in vivo.
Previous studies have shown that the proteasome inhi-
bitor MG-132 reduces the degradation of ubiquitin-
conjugated proteins in mammalian cells without affecting
ATPase or isopeptidase activities. MG-132 has been
reported to increase levels of E6 and E7 proteins in cervi-
cal cancer cells [14,15]. We also observed such increase
in HPV16+ cervical cancer cells CasKi and SiHa in vitro
and in vivo [8,9]. In this work we utilized the ability of E6
levels to respond to treatment with MG132 as a test to
confirm the stable expression of E6 by the transfected
cell line. Our 2A3 cell line was also responsive to treat-
ment with MG132.
Our final aim was to perform the proof of principle
RIT experiments targeting E6 in HNSCC with the radi-
olabeled mAb to this oncoprotein using novel HPV+
2A3 cell line and animal model. Targeting of viral anti-
gens within the tumors is fundamentally different from
traditional RIT, which aims for cell surface associated
tumor markers. The distinctive features of this approach
are: 1) the targets are of viral origin as opposed to “self”
human antigens, which minimizes cross-reactivity with
host tissues, and 2) the viral proteins normally reside in
intracellular compartments, such as the intranuclear
location of the E6 and E7 oncoproteins. The significant
decrease in tumor progression in mice with 2A3 tumors
treated with low dose of
188Re-C1P5 mAb is encoura-
ging as HNSCC is known to be resistant to external
beam radiation therapy which in combination with che-
motherapy is a standard treatment modality for this
cancer [16]. Higher doses of radiolabeled mAbs to E6 or
their repeated administration which we are planning to
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Figure 3 In vitro growth analysis of both FaDu and the HPV
transfected cell line, 2A3. Approximately 5 × 10
4 cells were plated
in a 6-well plate and grown at 37°C for 6 days.
b) a)
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Figure 4 Western Blot showing positive E6 expression from
various protein extracts. All samples were normalized with a
tubulin control: a) 2A3 and FaDu cells grown in vitro; b) comparison
of E6 levels in CasKi cervical cancer cells (lane1) and in 2A3 cells
(lane 2). The intensity of the bands was compared using ImageJ
software; c) 2A3 cells grown in vitro and treated with various
concentrations of MG-132 for 3 hours. Lane 1-4 - 0, 5, 10 and
25 μg/ml MG-132, respectively; d) 2A3 and FaDu tumors in nude
mice with and without treatment with 20 μg/ml of the proteasome
inhibitor MG-132 3 hrs before extraction of the tumors (lanes 1 and
2 - 2A3, lanes 3 and 4 - FaDu).
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have more long-lasting tumoricidal effects. In the con-
trol groups used in the proof of principle study “cold”
m A bt oE 6C 1 P 5a l s os l o w e dd o w nt h et u m o rg r o w t h
though not as pronounced as the radiolabeled mAb to
E6. A similar effect on the tumor growth by the “cold”
C1P5 was observed in experimental cervical cancer (8;
Phaeton R. et al. unpublished observations) which was
accompanied by complement deposition and invasion of
inflammatory cells pointing at the involvement of com-
plement dependent cytotoxicity (CDC) and antibody
dependent cellular cytotoxicity (ADCC). The latter two
have been recently observed in melanoma tumor bearing
nude mice treated with “cold” antibody [17]. Thus, taken
together these observations present attractive avenues
for the development of molecular therapies for HNSCC
Figure 5 Radioimmunotherapy of 2A3 tumors in mice. Mice with tumors measuring 0.5-0.7 cm in diameter were randomized into groups of
five. The groups were treated IP with either: 200 μCi
188Re-C1P5 mAb, matching amount (6 μg) of “cold” C1P5 mAb; or left untreated. Mice were
observed for tumor growth and survival for 15 days. The experiment was performed twice. The differences in the tumor sizes between
188Re-
C1P5 mAb and untreated group were significant (P < 0.05) for all time points; the differences in the tumor sizes between
188Re-C1P5 mAb and
“cold” C1P5 mAb group were significant (P < 0.05) for Day 3-9 time points.
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line and animal model.
Conclusions
We describe the proof of principle RIT experiments tar-
geting E6 oncoprotein in HPV16+ experimental HNSCC
which can provide a valuable new approach to treatment
of HPV+ HNSCC. The novel stably transformed HPV16+
HNSCC cell line and animal model used in this study
were generated using easy, reproducible method of trans-
fection from the commercially available cell line FaDu.
Acknowledgements
The research was partially supported by: Mary Kay Ash Foundation grant,
Einstein NIH-designated Cancer Center, Center for AIDS Research, Albert
Einstein College of Medicine, and NIH grant AI60507 (ED).
Author details
1Department of Nuclear Medicine, Albert Einstein College of Medicine, Albert
Einstein Cancer Center, Bronx, New York, USA.
2The Faculty of Life sciences,
Hubei University, Wuhan, PR China.
3Department of Obstetrics & Gynecology
and Women’s Health, Division of Gynecologic Oncology, Albert Einstein
College of Medicine, Bronx, New York, USA.
4Department of Microbiology
and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
5Department of Medicine, Albert Einstein College of Medicine, Bronx, New
York, USA.
Authors’ contributions
All authors read and approved the final manuscript. ED designed the study;
AC, XGW and GG contributed to the design of the study; MH, ZJ, XGW and
ED performed the experiments and analyzed the results; ED, AC and GG
wrote the paper.
Authors’ information
ED in collaboration with AC pioneered the use of radioimmunotherapy
for treatment of infectious diseases as before it was exclusively a cancer
treatment modality. They subsequently expanded this approach to
treatment of cancers of viral origin. ED is an Associated Professor of Nuclear
Medicine and Microbiology and Immunology at the Albert Einstein College
of Medicine and is a Sylvia and Robert S. Olnick Faculty Scholar in Cancer
Research.
Competing interests
ED and AC are among co-inventors on the US patent application
“Radioimmunotherapy and imaging of tumor cells that express viral
antigens”.
Received: 28 November 2010 Accepted: 12 February 2011
Published: 12 February 2011
References
1. Hoffmann M, Lohrey C, Hunziker A, Kahn T, Schwarz E: Human
papillomavirus type 16 E6 and E7 genotypes in head-and-neck
carcinomas. Oral Oncology 2004, 40:520-524.
2. Kaur P, McDougall JK, Cone R: Immortalization of primary human
epithelial cells coned cervical carcinoma DNA containing human
papillomavirus type E6/E7 open reading frames. J Gen Virol 1989,
70:1261-1266.
3. Kaur P, McDougall JK: HPV-18 immortalization of human keratinocytes.
Virology 1989, 173:302-310.
4. Percoraro G, Morgan D, Defendi V: Differential effects of human
papillomavirus type 6, 16, and 18 DNAs on immortalization and
transformation of human cervical epithelial cells. Proc Natl Acad Sci USA
1989, 86:563-567.
5. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF,
Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC,
Redmond KP, Gillison ML: Human Papillomavirus and Survival of Patients
with Oropharyngeal Cancer. N Engl J Med 2010.
6. Sharkey RM, Goldenberg DM: Targeted therapy of cancer: new prospects
for antibodies and immunoconjugates. CA Cancer J Clin 2006, 56:226-243.
7. Dadachova E, Wang XG, Casadevall A: Targeting the virus with
radioimmunotherapy in virus-associated cancer. Cancer Biother
Radiopharm 2007, 22:303-308.
8. Wang XG, Revskaya E, Bryan RA, Strickler HD, Burk RD, Casadevall A,
Dadachova E: Treating cancer as an infectious disease - viral antigens as
novel targets for treatment and potential prevention of tumors of viral
etiology. PLoS ONE 2007, 2:e114.
9. Phaeton R, Wang XG, Einstein MH, Goldberg GL, Casadevall A, Dadachova E:
The influence of proteasome inhibitor MG132, external radiation, and
unlabeled antibody on the tumor uptake and biodistribution of (188)Re-
labeled anti-E6 C1P5 antibody in cervical cancer in mice. Cancer 2010,
116(S4):1067-1074.
10. Phaeton R, Harris M, Jiang Z, Wang XG, Einstein MH, Goldberg GL,
Casadevall A, Dadachova E: Radioimmunotherapy with antibody to HPV-
16 E6 oncoprotein is effective in experimental cervical tumor expressing
low levels of E6. Cancer Biol Ther 2010.
11. Hoffmann TK, Sonkoly E, Hauser U, van Lierop A, Whiteside TL,
Klussmann JP, Hafner D, Schuler P, Friebe-Hoffmann U, Scheckenbach K,
Erjala K, Grénman R, Schipper J, Bier H, Balz V: Alterations in the p53
pathway and their association with radio- and chemosensitivity in head
and neck squamous cell carcinoma. Oral Oncol 2008, 44(12):1100-9.
12. Rangan SRS: A new human cell line (FaDu) from a hypopharyngeal
carcinoma. Cancer 2006, 29:117-121.
13. Schlecht NF, Burk RD, Adrien L, Dunne A, Kawachi N, Sarta C, Chen Q,
Brandwein-Gensler M, Prystowsky MB, Childs G, Smith RV, Belbin TJ: Gene
expression profiles in HPV-infected head and neck cancer. J Pathol 2007,
213:283-93.
14. Kehmeier E, Rühl H, Voland B, Stöppler MC, Androphy E, Stöppler H:
Cellular steady-state levels of “high risk” but not “low risk” human
papillomavirus (HPV) E6 proteins are increased by inhibition of
proteasome dependent degradation independent of their p53- and
E6AP-binding capabilities. Virology 2002, 299:72-87.
15. Oh KJ, Kalinina A, Wang J, Nakayama K, Nakayama KI, Bagchi S:
The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and
Cullin 1- and Skp2-containing E3 ligase. J Virol 2004, 78:5338-5346.
16. Sher DJ, Haddad RI, Norris CM Jr, Posner MR, Wirth LJ, Goguen LA,
Annino D, Balboni T, Allen A, Tishler RB: Efficacy and toxicity of
reirradiation using intensity-modulated radiotherapy for recurrent or
second primary head and neck cancer. Cancer 2010.
17. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M,
Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS,
Sayegh MH, Frank MH: Identification of cells initiating human
melanomas. Nature 2008, 451(7176):345-9.
doi:10.1186/1758-3284-3-9
Cite this article as: Harris et al.: Radioimmunotherapy of experimental
head and neck squamous cell carcinoma (HNSCC) with E6-specific
antibody using a novel HPV-16 positive HNSCC cell line. Head & Neck
Oncology 2011 3:9.
Table 1 P values for comparison of tumor sizes in
188Re-C1P5 mAb group to control groups in the
RIT experiment
Control group Days post-treatment
369 1 2 1 5
untreated 0.01 0.01 0.01 0.03 0.03
"Cold" C1P5 0.02 0.01 0.045 0.08 0.10
The differences between the tumor sizes for differently treated groups were
analyzed by non-parametric Mann-Whitney test. Statistically significant P
values are in bold.
Harris et al. Head & Neck Oncology 2011, 3:9
http://www.headandneckoncology.org/content/3/1/9
Page 7 of 7